Edwards Lifesciences Corp (EW) Financial Statements
Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
In fiscal 2025, Edwards Lifesciences reported revenue of $6.07B, up 11.5% from $5.44B the year before. Net income was $1.07B (a 17.7% net margin), or $1.83 per diluted share. Gross margin was 78.0% and operating margin was 20.8%. Operating activities generated $1.60B of cash, leaving $1.33B of free cash flow. At fiscal year end, Edwards Lifesciences held $13.70B in total assets against $3.36B in total liabilities, including $2.94B of cash and equivalents.
Open the full interactive Edwards Lifesciences financials → Quarterly statements, key ratios, valuation history and price charts.
Edwards Lifesciences Key Stats
| Share Price | $85.27 |
|---|---|
| Market Cap | $49.25B |
| P/E Ratio | 46.6 |
| Revenue YoY Growth | +11.6% |
| 52-Week Range | $72.65 – $95.18 |
| Shares Outstanding | 576.4 million (basic, 2026 Q2) |
Edwards Lifesciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $4.39B | $5.23B | $5.38B | $6.00B | $5.44B | $6.07B |
| Cost of Goods Sold | $1.08B | $1.25B | $1.08B | $1.38B | $1.12B | $1.33B |
| Gross Profit | $3.31B | $3.98B | $4.30B | $4.62B | $4.32B | $4.73B |
| Operating Income | $897.6M | $1.69B | $1.75B | $1.53B | $1.38B | $1.26B |
| Pre-Tax Income | $916.7M | $1.70B | $1.77B | $1.60B | $1.55B | $1.27B |
| Income Tax | $93.3M | $198.9M | $245.5M | $198.7M | $152.1M | $216.9M |
| Net Income | $823.4M | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B |
| Diluted EPS | $1.30 | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
Edwards Lifesciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.55B | $1.57B | $1.65B | $1.74B |
| Net Income | $291.1M | $91.2M | $380.7M | $241.9M |
| Diluted EPS | $0.50 | $0.16 | $0.66 | $0.42 |
Edwards Lifesciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.18B | $862.8M | $769.0M | $1.14B | $3.05B | $2.94B |
| Current Assets | $3.09B | $3.18B | $3.10B | $4.04B | $6.29B | $6.74B |
| Total Assets | $7.24B | $8.50B | $8.29B | $9.36B | $13.06B | $13.70B |
| Current Liabilities | $893.9M | $1.03B | $1.02B | $1.20B | $1.51B | $1.81B |
| Total Long-Term Debt | $595.0M | $595.7M | $596.3M | $597.0M | $597.7M | $598.3M |
| Total Liabilities | $2.66B | $2.67B | $2.49B | $2.64B | $2.99B | $3.36B |
| Shareholders' Equity | $4.57B | $5.84B | $5.81B | $6.65B | $10.00B | $10.34B |
Edwards Lifesciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $1.05B | $1.73B | $1.22B | $895.8M | $542.3M | $1.60B |
| Cash From Investing | -$531.1M | -$1.72B | $252.3M | $173.8M | $2.31B | -$712.9M |
| Cash From Financing | -$486.9M | -$356.3M | -$1.58B | -$711.0M | -$983.0M | -$956.8M |
| Free Cash Flow | $647.3M | $1.41B | $973.6M | $642.8M | $289.9M | $1.33B |
Figures from Edwards Lifesciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Edwards Lifesciences financials page for every line item.
Edwards Lifesciences Company Profile
| Ticker | EW |
|---|---|
| Exchange | NYSE |
| Industry | Orthopedic, Prosthetic & Surgical Appliances & Supplies |
| Headquarters | Irvine, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001099800 |
Frequently Asked Questions
What was Edwards Lifesciences' revenue in fiscal 2025?
Edwards Lifesciences (EW) reported revenue of $6.07B for fiscal 2025.
What is Edwards Lifesciences' annual revenue history?
Edwards Lifesciences' annual revenue by fiscal year: 2020: $4.39B; 2021: $5.23B; 2022: $5.38B; 2023: $6.00B; 2024: $5.44B; 2025: $6.07B.
What was Edwards Lifesciences' net income in fiscal 2025?
Edwards Lifesciences reported net income of $1.07B for fiscal 2025.
What was Edwards Lifesciences' earnings per share (EPS) in fiscal 2025?
Edwards Lifesciences' diluted EPS was $1.83 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Edwards Lifesciences generate in fiscal 2025?
Edwards Lifesciences generated $1.33B of free cash flow in fiscal 2025.
What was Edwards Lifesciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Edwards Lifesciences reported revenue of $1.74B.
How much debt does Edwards Lifesciences have?
Edwards Lifesciences reported $598.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Edwards Lifesciences are outstanding?
Edwards Lifesciences reported a weighted average of 576.4 million basic shares outstanding in 2026 Q2.
What is Edwards Lifesciences' market cap?
Based on its latest closing price, Edwards Lifesciences (EW) has a market capitalization of about $49.25B.
When does Edwards Lifesciences' fiscal year end?
Edwards Lifesciences' fiscal year end, as registered with the SEC, is December 31.
Where is Edwards Lifesciences headquartered?
Edwards Lifesciences lists its business address in Irvine, California in its SEC filings.
Edwards Lifesciences Competitors & Similar Companies
See all 20 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies →